SEC22B and neoplasm: Identification of several critical players in antigen cross-presentation, such as Sec22b (4), or Rab43 (40), and their subsequent validation in conditional knock-out mouse pre-clinical models established a major role for this pathway in different types of immunes responses, including anti-tumor immune responses.